Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis

Dig Liver Dis. 2000 Jun-Jul;32(5):406-11. doi: 10.1016/s1590-8658(00)80261-3.

Abstract

Background: Pancreatic exocrine insufficiency is a common condition in patients with cystic fibrosis. Large amounts of pancreatic enzyme supplements are required to reduce malabsorption but patient compliance is not always optimal.

Aims: To compare patients' preference and the efficacy of two enteric coated microsphere preparations in patients with cystic fibrosis.

Patients: Patients with pancreatic exocrine insufficiency due to cystic fibrosis.

Methods: Patients were assigned to the crossover treatment with Creon or Pancrease for 1 week and then to the alternative treatment. Patients had to follow a fixed diet (at least 2 g fat/kg) and had to assume 1000 units lipase/g fat. The evaluation parameters were: patients' preference, acceptance of therapy, stool fat excretion, stool weight, gastrointestinal symptoms, and tolerance.

Results and conclusions: Of the 33/60 patients who expressed a preference for one of the two treatments, 30 preferred Creon while only 3 patients preferred Pancrease (p<0.001). No difference between the two treatments was observed regarding stool characteristics, gastrointestinal symptoms and tolerance. The mean number of capsules taken daily was reduced by 35% with Creon. The results of this study showed a preference in favour of Creon probably due to the reduction of daily capsule intake of 35%, supporting digestion as well as Pancrease.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Amylases / administration & dosage
  • Capsules
  • Child
  • Cystic Fibrosis / complications*
  • Drug Tolerance
  • Endopeptidases / administration & dosage
  • Exocrine Pancreatic Insufficiency / drug therapy*
  • Exocrine Pancreatic Insufficiency / etiology
  • Female
  • Gastrointestinal Agents / administration & dosage*
  • Humans
  • Lipase / administration & dosage
  • Male
  • Microspheres
  • Pancrelipase / administration & dosage*
  • Patient Acceptance of Health Care
  • Safety

Substances

  • Capsules
  • Gastrointestinal Agents
  • Pancrelipase
  • Lipase
  • Amylases
  • Endopeptidases